Literature DB >> 15126075

The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs.

Catherine T Anthony1, Susan Hughey, John Lyons, Sean Weiss, Conrad A Hornick, George J Drouant, Joseph A Fuselier, David H Coy, William A Murphy, Eugene A Woltering.   

Abstract

BACKGROUND: Creation of protease-resistant somatostatin analogs has allowed development of these peptides as clinically useful drugs. Widespread diagnostic use of radiolabeled somatostatin analogs has enhanced interest in the binding and intracellular distribution of these peptides. The degree of drug internalization and length of drug retention may be critical for drug-induced cytotoxicity. We hypothesized that the ability of a radiolabeled peptide to bind to a cell, be internalized, and induce cytotoxicity is proportional to both the radioligand concentration and the exposure time.
MATERIALS AND METHODS: To test this hypothesis, somatostatin receptor-expressing cells (IMR-32) were incubated with (111)In-pentetreotide, a sst 2 preferring somatostatin analogue. Radioligand exposure time and/or concentration were varied.
RESULTS: Prolonged exposure to a fixed concentration of radioligand resulted in progressive increases in whole cell binding and internalization over time. Cells exposed to a relatively fixed number of microCi-Hr yielded constant whole cell binding and internalization. Increasing the microCi-Hr resulted in a proportionate increase in binding. Cytotoxicity was also proportional to the dose of radiation regardless of whether the exposure was internalized radiation (microCi-Hr from (111)In-pentetreotide) or from external beam radiation (cGy).
CONCLUSION: Both drug exposure time and drug concentration contribute to cell binding and cytotoxicity in this model and their relative contributions are inversely related.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126075     DOI: 10.1016/j.jss.2003.06.002

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

1.  Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.

Authors:  Jean Claude Reubi; Beatrice Waser; Renzo Cescato; Beat Gloor; Christoph Stettler; Emanuel Christ
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

2.  Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice.

Authors:  Li-Chun Sun; L Vienna Mackey; Jing Luo; Joseph A Fuselier; David H Coy
Journal:  Clin Med Oncol       Date:  2008-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.